Frequency Therapeutics (Frequency Therapeutics) Asset Impairment Charge : $0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Frequency Therapeutics Asset Impairment Charge?

Frequency Therapeutics's Asset Impairment Charge for the three months ended in Jun. 2023 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Frequency Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Frequency Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frequency Therapeutics Asset Impairment Charge Chart

Frequency Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Asset Impairment Charge

Get a 7-Day Free Trial

Frequency Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Frequency Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Frequency Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Frequency Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Frequency Therapeutics (Frequency Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frequency Therapeutics Inc (NAS:FREQ) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Hayden Avenue, Suite 300, Lexington, MA, USA, 02421

Website

https://www.frequencytx.com

Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss.

Executives

Richard J. Mitrano	officer: VP Finance & Operations	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
David L. Lucchino	director, officer: President and CEO	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Christopher R. Loose	officer: Chief Scientific Officer	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Quentin Mccubbin	officer: Chief Manufacturing Officer	C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Wendy S Arnold	officer: Chief People Officer	19 PRESIDENTIAL WAY, SUITE 203, WOBURN MA 01801
Carl Lebel	officer: Chief Development Officer	23256 MARIPOSA DE ORO, MALIBU CA 90265
Peter P. Pfreundschuh	officer: Chief Financial Officer	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Michael Bookman	officer: General Counsel and Secretary	C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Joel S Marcus	director, 10 percent owner	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Cynthia L Feldmann	director	17 WINTHROP ROAD, WAYLAND MA 01778
Marc A Cohen	director	1000 WILSON BLVD. #1800, ARLINGTON VA 22209
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p.	10 percent owner, other: Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Alexandria Venture Investments, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101